Drug class in one race
ALK drugs for Non-Small Cell Lung Cancer
6 tracked ALK drugs in the Non-Small Cell Lung Cancer race. The class explanation lives on the ALK page; the full indication pipeline across every mechanism is on the Non-Small Cell Lung Cancer page.
4 approved / phase 41 Phase 31 Phase 1
Head-to-head evidence: Alectinib vs AQUA07 · AQUA07 vs Brigatinib · AQUA07 vs Ceritinib · AQUA07 vs Ensartinib · Alectinib vs Brigatinib · Alectinib vs Ceritinib